ONX 0912, a Novel Oral Proteasome Inhibitor (PI), In Patients (pts) With Advanced Refractory or Recurrent Solid Tumours: a Phase 1, Open-label, Dose Escalation Study

被引：1
|
作者：
Papadopoulos, K. [1 ]
Mendelson, D. [2 ]
Tolcher, A. W. [1 ]
Burris, H. A. [3 ]
Gordon, M. [2 ]
Wong, H. [4 ]
Bomba, D. [4 ]
Lee, S. [4 ]
Gillenwater, H. [4 ]
Infante, J. [3 ]
机构：
[1] Start Ctr Canc Care, San Antonio, TX USA
[2] Premiere Oncol, Oncol, Scottsdale, AZ USA
[3] Tennessee Oncol, Oncol, Nashville, TN USA
[4] Onyx Pharmaceut, Oncol, San Francisco, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)70821-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S147 / S147
页数：1
相关论文
共 50 条
  • [31] Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial
    Song, Yan
    Wang, Jinwan
    Ren, Xiubao
    Jin, Jie
    Mao, Li
    Liang, Chris
    Ding, Lieming
    Yang, Lin
    [J]. CHINESE JOURNAL OF CANCER RESEARCH, 2021, 33 (01) : 103 - +
  • [32] A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
    Michael S. Gordon
    David S. Mendelson
    Mitchell Gross
    Martina Uttenreuther-Fischer
    Mahmoud Ould-Kaci
    Yihua Zhao
    Peter Stopfer
    David B. Agus
    [J]. Investigational New Drugs, 2013, 31 : 409 - 416
  • [33] A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
    Gordon, Michael S.
    Mendelson, David S.
    Gross, Mitchell
    Uttenreuther-Fischer, Martina
    Ould-Kaci, Mahmoud
    Zhao, Yihua
    Stopfer, Peter
    Agus, David B.
    [J]. INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 409 - 416
  • [34] SUBCUTANEOUS DARATUMUMAB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE 1B STUDY (PAVO)
    Mateos, M., V
    Chari, A.
    Nah, H.
    Lokhorst, H.
    Kaufman, J. L.
    Moreau, P.
    Oriol, A.
    Plesner, T.
    Benboubker, L.
    Hellemans, P.
    Masterson, T.
    Clemens, P. L.
    Liu, K.
    San-Miguel, J.
    Usmani, S. Z.
    [J]. HAEMATOLOGICA, 2018, 103 : 32 - 33
  • [35] A multicenter, open-label, dose-escalation, first-in-man study of MetAP2 inhibitor M8891 in patients with advanced solid tumours
    Carducci, M. A.
    Wang, D.
    Habermehl, C.
    Boedding, M.
    Rohdich, F.
    Stinchi, S.
    Karpenko, O.
    Gimmi, C.
    LoRusso, P.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S486 - S486
  • [36] Phase I open-label, dose escalation and expansion study of YH003, an anti-CD40 agonist monoclonal antibody in combination with toripalimab in patients (pts) with advanced solid tumours
    Markman, B.
    Coward, J.
    Nagrial, A.
    Abed, A.
    Millward, M.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S632 - S632
  • [37] Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial
    Loeb, David M.
    Lee, Ji Won
    Morgenstern, Daniel A.
    Samson, Yvan
    Uyttebroeck, Anne
    Lyu, Chuhl Joo
    Van Damme, An
    Nysom, Karsten
    Macy, Margaret E.
    Zorzi, Alexandra P.
    Xiong, Julia
    Pollert, Petra
    Joerg, Ingrid
    Vugmeyster, Yulia
    Ruisi, Mary
    Kang, Hyoung Jin
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (10) : 2485 - 2495
  • [38] Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial
    David M. Loeb
    Ji Won Lee
    Daniel A. Morgenstern
    Yvan Samson
    Anne Uyttebroeck
    Chuhl Joo Lyu
    An Van Damme
    Karsten Nysom
    Margaret E. Macy
    Alexandra P. Zorzi
    Julia Xiong
    Petra Pollert
    Ingrid Joerg
    Yulia Vugmeyster
    Mary Ruisi
    Hyoung Jin Kang
    [J]. Cancer Immunology, Immunotherapy, 2022, 71 : 2485 - 2495
  • [39] A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumours
    Harb, W.
    Patnaik, A.
    Mahalingam, D.
    Liu, J.
    Wen, P. Y.
    Shapiro, G. I.
    Bullock, A. J.
    Juric, D.
    Zheng, L.
    Moore, K.
    Patel, M.
    Guttendorf, R.
    Wang, S.
    Kerstein, K.
    Berk, G.
    Cieslewicz, M. J.
    Watnick, J.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [40] A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors.
    Park, Jong Chul
    Butler, Marcus O.
    Curti, Brendan D.
    Emens, Leisha A.
    Pastor, Danielle M.
    Elassal, Joseph
    Kaufman, Howard L.
    Kirkwood, John M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345